Oxygen-evolving hollow polydopamine alleviates tumour hypoxia for enhancing photodynamic therapy in cancer treatment.

Authors :: Zhan Q
Han X
Mu J
Shi X
Zheng Y
Wang T
Cao T
Xi Y
Weng Z
Wang X
Cao P
Source :: Nanoscale advances [Nanoscale Adv] 2022 Oct 19; Vol. 4 (23), pp. 5021-5026. Date of Electronic Publication: 2022 Oct 19 (Print Publication: 2022).
Publication Year :: 2022
Abstract: Hypoxia, a characteristic hallmark of solid tumours, restricts the therapeutic effect of photodynamic therapy (PDT) for cancer treatment. To address this issue, a facile and nanosized oxygen (O <subscript>2</subscript> ) bubble template is established by mixing oxygenated water and water-soluble solvents for guiding hollow polydopamine (HPDA) synthesis, and O <subscript>2</subscript> is encapsulated in the cavity of HPDA. HPDA with abundant catechol is designed as a carrier for zinc phthalocyanine (ZnPc, a boronic acid modified photosensitizer) via borate ester bonds to fabricate nanomedicine (denoted as HZNPs). The in vitro and in vivo results indicate that O <subscript>2</subscript> -evolving HZNPs could alleviate tumour hypoxia and enhance PDT-anticancer efficiency. Melanin-like HPDA with a photothermal conversion rate ( η ) of 38.2% shows excellent synergistic photothermal therapy (PTT) efficiency in cancer treatment.<br />Competing Interests: There are no conflicts to declare.<br /> (This journal is © The Royal Society of Chemistry.)

Full Text Access

Tools